by John Conrad | Aug 1, 2025 | Member News, NewsBrief
Chicago biotech startup ClostraBio has secured GRAS (Generally Recognized as Safe) status for its flagship probiotic ingredient CLB101™, clearing the path for the first commercially available strain of Anaerostipes caccae in the U.S. What Makes It Different Unlike...
by John Conrad | Jan 8, 2025 | Grants, NewsBrief
In partnership with G2G Consulting, we are please to provide the January 2025 Grants report, showcasing 196 non-dilutive government funding opportunities across diverse biomedical and life sciences sectors. The comprehensive report underscores significant funding...
by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
by John Conrad | Oct 30, 2024 | Member News, NewsBrief
Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain’s Chicago Business and...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
AbbVie announced today it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer’s disease research. The acquisition gives AbbVie access to Aliada’s novel blood-brain barrier crossing...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
